Latest news with #ScottSneddon
Yahoo
22-05-2025
- Business
- Yahoo
Sharp Therapeutics Corp. Reports First Quarter 2025 Results
Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - May 22, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical-stage biotechnology company developing small molecule therapies to treat genetic diseases, announces the release of its condensed interim consolidated financial statements for the three months ended March 31, 2025, and related management discussion and analysis. All dollar figures are in United States dollars, unless otherwise stated. Scott Sneddon, Sharp's Chief Executive Officer, stated: "Our Q1 financial results show our continued investment in research and development programs, mainly our Gaucher's and Progranulin programs. We spent 74% more than the comparable quarter in 2024 which has led to reaching a key milestone to nominate a clinical candidate for Gaucher's. Our investment will continue as we aim to our next milestone of entering Phase I clinical trials in 2026." Recent Sharp Highlights On April 21, 2025, STX PARTNERS LLP and Newlin Investment Company each exercised their respective common share purchase warrants of the Company for aggregate gross proceeds to the Company of $2.5M at an exercise price of $1.45743 per share. On May 13, 2025, the Company announced it had nominated its first clinical candidate from its GBA program for development in Gaucher's disease. Upcoming Event On June 5, 2025, the scientific data supporting the compounds for the Sharp Gaucher's Program will be presented at the GBA1 Conference in Montreal starting of which Sharp is also a meeting sponsor. About Sharp Therapeutics Corp. First-Choice Therapies for Genetic Diseases Sharp Therapeutics is a pre-clinical stage company developing first-choice small-molecule therapeutics for genetic diseases. The Company's discovery platform combines novel high throughput screening technologies, with compound libraries computational optimized based on the physics and biology of cellular trafficking defects and allosteric activation of proteins. The platform produces small molecule compounds that restore activity in mutated proteins giving the potential to treat genetic disorders with conventional pill-based medicines. For additional information on Sharp, please visit: Sharp Therapeutics Corp. Scott Sneddon, PhD, JDCEO/CSO Email: scott@ Caution Regarding Forward-Looking Information Certain statements contained in this press release constitute "forward-looking information" as such term is defined in applicable Canadian securities legislation. The words "may", "would", "could", "should", "potential", "will", "seek", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions are intended to identify forward-looking information. All statements other than statements of historical fact may be forward-looking information. Such statements reflect Sharp's current views and intentions with respect to future events, and current information available to Sharp, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. Should any factor affect Sharp in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, Sharp does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and Sharp undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Scotsman
07-05-2025
- Business
- Scotsman
InchDairnie distillery debuts inaugural single malt KinGlassie whiskies
Fife-based Scotch whisky-maker InchDairnie Distillery is launching its first Single Malt Scotch Whisky - and there are two to enjoy. Further showcasing its reputation as a pioneer in flavour exploration in the whisky sector, KinGlassie Double Matured Aged 8 Years Fife Single Malt Scotch Whisky and KinGlassie Raw Aged 8 Years Fife Single Malt Scotch Whisky launch on 8 May 2025. The new offerings from InchDairnie, which is located in Glenrothes, are contenders for the first peated whisky from the Kingdom of Fife in modern times. The two whiskies debuting comprise KinGlassie Double Matured and KinGlassie Raw, each providing a distinct take on the new KinGlassie range that ignites flavour discovery, revealing new dimensions in smoke. KinGlassie, which is taken from the Irish 'Saint Glaisne' means 'church by the burn' and is also the name of the village near the distillery's base. KinGlassie Double Matured is a heavily peated eight-year-old single malt whisky, with a distinctive 50ppm peat content derived from Scottish mainland peat. Until 2021, it was distilled only once a year for less than a week. Crafted at InchDairnie Distillery, this whisky benefits from innovative equipment, such as the hammer mill that finely grinds grain to maximise flavour extraction and a mash conversion vessel that replaces the traditional mash tun, ensuring a richer, more refined character. KinGlassgie Double Matured whisky Double distilled and double condensed for more copper contact to remove sulphur notes, KinGlassie Double Matured is first matured in Bourbon casks for five years and then Amontillado casks for three years. Tasting notes includes a combination of smoke and tobacco, with rich layers of almonds and nuts, creating a smoky and velvety drinking experience. The limited edition KinGlassie Raw brings a smouldering fireplace hit, with a complex depth charge of rich, sweet, malty flavours. It is aged for eight years in American oak ex-bourbon casks. The two products complement InchDairnie's existing product offering, RyeLaw, a single distillery Scottish Rye Whisky made from malted rye and barley. InchDairnie Distillery is working with partners such as the Scotch Whisky Association (SWA) to promote responsible peat use and extraction practices. The distillery is also working to support peatland restoration projects, collaborating with other distilleries, landowners and organisations such as NatureScot Peatland Action and IUCN, to restore degraded peatlands and contribute to the broader environmental goals of the whisky industry. Scott Sneddon, managing director at InchDairnie Distillery said: 'We are extremely excited to bring these products to market and believe they will be well suited to fans of highly peated whiskies but also to those who are seeking something different. 'KinGlassie very much demonstrates our ethos of fusing centuries-old tradition with our innovation-led laser focus on creating multi-layered flavour to create a whisky that is luxuriously smoky and smooth. 'We are also pleased to be building out our product range, with further launches in the coming years, as InchDairnie Distillery gains a prominent role in Scotland's Scotch sector.' KinGlassie Raw whisky Ian Palmer, founder at InchDairnie Distillery added: 'I am incredibly proud to mark this moment as a landmark milestone for InchDairnie Distillery. "The launch of KinGlassie Double Matured and KinGlassie Raw is a huge step in our journey, not just as a distillery but as innovators in the whisky industry. "These two distinct whiskies represent our unwavering commitment to pushing the boundaries of flavour and delivering a taste revolution. I believe it will become a gamechanger for those who crave complexity, and depth.' KinGlassie Double Matured and KinGlassie Raw launch on 8 May 2025 priced with a RRP of £79. You can buy the whiskies here. KinGlassie Raw will be exclusively available for one month through The Whisky Exchange and Speciality Drinks, and then all good whisky retailers and direct from the distillery website.
